Video
Author(s):
Elissa Engel, MD, pediatric resident, University of South Florida, discusses the successful use of eltrombopag (Promacta) in a pediatric patient with HIV-related thrombocytopenia.
Elissa Engel, MD, pediatric resident, University of South Florida, discusses the successful use of eltrombopag (Promacta) in a pediatric patient with HIV-related thrombocytopenia.
A 13-year old patient presented with HIV, which Engel says was most likely acquired prenatally. The patient was treated with first-line therapies including intravenous immunoglobulin (IVIg), but had poor response. After 2 years, the patient required treatment every 3 to 4 weeks, showed response, but then had symptomatic thrombocytopenia.
To treat the thrombocytopenia, Engel and her colleagues decided to treat the patient with eltrombopag based on information gathered from previous literature on the agent. Eltrombopag was dosed at 50 mg per day. The patient showed a clinical response, and has remained asymptomatic since starting the medication. This may imply that eltromopag can be used in patients who do not respond to first-line therapy, Engel says.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
2 Commerce Drive
Cranbury, NJ 08512